Stock Ratings / Health Care / NEOG / earnings

CLDX (41) NTLA (33) ORKA (53) LNTH (74) ⌘ Pro Terminal →

Neogen Corporation (NEOG) Next Earnings Date & Expected ±11.3% Move

$12.26 +1.16% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $12.26

Neogen Corporation (NEOG) carries a Roarable Rating of D+ (Sell) with 52/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 52/100 (D+) historically posted market-perform odds over rolling 90-day windows (-1.1% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $2.68B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $12.26 (+0.02%)🧬 Disciplined Float (-0.12% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 9.6% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 52/100 (D+) historically posted market-perform odds over rolling 90-day windows (-1.1% avg 90D alpha vs SPY • 50.1% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-2.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NEOG)Realized 20D OHLCV Swing Band: ±11.3%

Deterministic 5-Pillar Attribution (52/100 Composite)

🔍 WHY NEOG SCORES 52/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+14/20 pts (27% of score)

20D Institutional Volume Accumulation (±11.3% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+13/20 pts (25% of score)

FRED Regime × Technicals: 78% of 52W Range • RSI-14 at 45.3 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Cash Engine Quality7/20 pts (-13 pt drag)

Capital intensity & 0% operating margin leave 13 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$11.85-0.3% Next Q

Q2 (-2Q)

Grade D$11.81+3.2% Next Q

Q3 (-1Q)

Grade D$12.19+0.6% Next Q

Current

Grade D+$12.26-1.1% Hist 90D α

Trajectory: D (44) → D+ (52)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NEOG Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NEOG currently carries a cautious 52/100 (D+) rating due to Cash Engine Quality (7/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($12.23) and Max Pain ($12.87) forces dealer call-delta covering toward $14.97.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.12% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NEOG• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “NEOG Beats Next Quarter EPS Consensus (Nov 29, 2026) & Holds Above 200D SMA”

YES 52%NO 48%Trade / Inspect Odds →

NEXT EST. WINDOW: Nov 29, 2026 (~27 DAYS)

Historical OHLCV Volatility ±11.3% Swing Band

±$1.39 Expected Swing

MODEL EARNINGS SETUP GAUGE

NEOG Quantitative Pre-Earnings Setup: 52/100

Trailing EPS: $4.25 • YoY Revenue Growth: -2.7%

Model Bullish Setup (52/100)Model Risk Weight (48/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2026-05-31	$870.4M	-$7.9M	$83.2M	46.9%
FY 2024	2025-05-31	$894.7M	-$1.09B	$58.2M	47.1%
FY 2023	2024-05-31	$924.2M	-$9.4M	$35.3M	46.9%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NEOG)

✓Walkthrough of NEOG's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NEOG // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +30.43%▲ ASCENDING CHANNEL

2026-10-30O $12.15H $12.26L $11.63C $12.26VOL 1.95M

RES: $15.32SUP: $10.22SMA50: $12.23SMA200: $10.42

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NEOG Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NEOG Butterfly Map → + Track NEOG →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -2.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on NEOG today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NEOG. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NEOG today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NEOG)

Health Care Rank #314 of 1016 ⚔️ CLDX vs NEOG Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NEOG vs. CLDX, NTLA, ORKA, LNTH)

Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances (18 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Neogen Corporation (NEOG) ranks #314 by composite RQD confidence (52/100, grade D+) and #216 by equity capitalization ($2.68B). Within this direct 5-issuer industry benchmark cohort, LNTH leads on earnings valuation at 28.0x trailing P/E, while LNTH leads on capital efficiency and profitability with 20.3% ROIC and 61.1% gross margin. LNTH currently holds the highest overall quantitative score in the immediate peer group at 74/100 (B) compared with NEOG at 52/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NEOG ACTIVE Neogen Corporation	D+	52/100	—	46.9%	-0.6%	+1.16%	$2.68B	Benchmark Subject
CLDX Celldex Therapeutics Inc.	D-	41/100	—	87.1%	-35.0%	+0.78%	$2.35B	/cldx-vs-neog →
NTLA Intellia Therapeutics Inc.	E	33/100	—	—	-35.0%	-0.68%	$1.85B	/ntla-vs-neog →
ORKA Oruka Therapeutics Inc.	D+	53/100	—	—	-18.8%	+0.71%	$6.40B	/orka-vs-neog →
LNTH Lantheus Holdings Inc.	B	74/100	28.0x	61.1%	20.3%	+0.22%	$6.55B	/lnth-vs-neog →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2026-05-31 • CIK 0000711377

In its most recent audited fiscal period (FY2025, filed 2026-05-31), Neogen Corporation (NEOG) reported GAAP revenue of $870.4M (-2.7% vs. FY2024 revenue of $894.7M , and -5.8% cumulative change since FY2023) , GAAP net income of -$7.9M, operating cash flow of $83.2M, and free cash flow of $83.2M (+43.0% YoY). On the balance sheet, NEOG closed FY2025 with $3.36B in total assets against $792.9M in total debt (Altman Z-Score: 1.45, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2026-05-31	$870.4M	-$7.9M	$83.2M	$83.2M	$3.36B	$792.9M
FY2024 (FY)	2025-05-31	$894.7M	-$1.09B	$58.2M	$58.2M	$4.05B	$889.9M
FY2023 (FY)	2024-05-31	$924.2M	-$9.4M	$35.3M	$35.3M	—	—

3. NEOG Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NEOG stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Neogen Corporation (NASDAQ: NEOG) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 52/100 at a spot price of $12.26 (+1.16% 1D, market cap $2.68B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 8/20. Across 1016 tracked Health Care issuers, NEOG ranks #314 in composite RQD confidence.

How does NEOG compare to CLDX and NTLA in the Health Care sector?

Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), NEOG carries a Roarable D+ (52/100 RQD), trailing P/E of N/A, gross margin of 46.9%, and ROIC of -0.6%. By comparison, CLDX (Celldex Therapeutics Inc.) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $2.35B) and NTLA (Intellia Therapeutics Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $1.85B). Among the 5-stock peer group, LNTH leads on earnings multiple (28.0x) while LNTH leads on capital efficiency (20.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NEOG?

Per NEOG's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-05-31, CIK 0000711377), Neogen Corporation generated $870.4M in revenue (-2.7% YoY), -$7.9M in net income, and $83.2M in free cash flow against $3.36B in total assets and $792.9M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NEOG trading relative to its 50-day, 200-day, and 52-week technical levels?

NEOG last traded at $12.26 (+1.16% on volume of 3,225,858 shares), positioning the stock +0.25% above its 50-day simple moving average ($12.23) and +17.66% above its 200-day simple moving average ($10.42). Across its 52-week range of $5.37 to $14.26, NEOG sits at the 77.5% percentile with a 14-day RSI of 45.3 (NEUTRAL RANGE) and an implied next-earnings move of ±11.3% ($10.87 to $13.65).

NEOG Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is NEOG's next earnings date?

Based on SEC filing cadence, Neogen Corporation (NEOG)'s next quarterly reporting window is estimated around Nov 29, 2026.

How much is NEOG stock expected to move on earnings?

Volatility modeling currently projects a ±11.3% event move for NEOG, spanning a range between $10.87 and $13.65.

Direct Sub-Reports: NEOG RQD Cockpit NEOG 12M Forecast NEOG Earnings & Move NEOG Dividends & DRIP NEOG Insiders & 13F NEOG Whale Options NEOG Profit Sankey NEOG News & Why